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Strengths and limitations of this study
 ► This is the first systematic review on methodological 
quality of prognostic models applied to resectable 
pancreatic cancer.
 ► This review is important and timely, as it is vital that 
the methodological quality of models designed to 
support medical decision-making are reviewed at a 
time when increasing focus and expectation is being 
placed on personalised predictive medicine.
 ► It highlights limitations in the existing body of re-
search and points towards the direction of future 
research.
 ► Due to lack of standardisation of reporting of out-
comes meta-analysis could not be performed.
 ► Initial title screening was limited to English language.
AbStrACt
Objectives To assess the methodological quality of 
prognostic model development studies pertaining to post 
resection prognosis of pancreatic ductal adenocarcinoma 
(PDAC).
Design/setting A narrative systematic review of 
international peer reviewed journals
Data source Searches were conducted of: MEDLINE, 
Embase, PubMed, Cochrane database and Google 
Scholar for predictive modelling studies applied to 
the outcome of prognosis for patients with PDAC post 
resection. Predictive modelling studies in this context 
included prediction model development studies with 
and without external validation and external validation 
studies with model updating. Data was extracted 
following the Checklist for critical Appraisal and 
data extraction for systematic Reviews of prediction 
Modelling Studies (CHARMS) checklist.
Primary and secondary outcome measures Primary 
outcomes were all components of the CHARMS checklist. 
Secondary outcomes included frequency of variables 
included across predictive models.
results 263 studies underwent full text review. 15 
studies met the inclusion criteria. 3 studies underwent 
external validation. Multivariable Cox proportional 
hazard regression was the most commonly employed 
modelling method (n=13). 10 studies were based 
on single centre databases. Five used prospective 
databases, seven used retrospective databases and 
three used cancer data registry. The mean number of 
candidate predictors was 19.47 (range 7 to 50). The 
most commonly included variables were tumour grade 
(n=9), age (n=8), tumour stage (n=7) and tumour size 
(n=5). Mean sample size was 1367 (range 50 to 6400). 
5 studies reached statistical power. None of the studies 
reported blinding of outcome measurement for predictor 
values. The most common form of presentation was 
nomograms (n=5) and prognostic scores (n=5) followed 
by prognostic calculators (n=3) and prognostic index 
(n=2).
Conclusions Areas for improvement in future 
predictive model development have been highlighted 
relating to: general aspects of model development and 
reporting, applicability of models and sources of bias.
trial registration number CRD42018105942
IntrODuCtIOn
Pancreatic cancer is the fourth and fifth most 
common cause of cancer deaths in USA and 
Europe, respectively.1 2 Long-term survival 
from pancreatic cancer remains poor despite 
advances in surgical technique and adjuvant 
treatment,3 yet risk of operative morbidity 
and mortality remains high with potential 
benefits of high-risk surgery often nullified by 
early disease recurrence.4 5 Prognostic models 
are therefore of great potential benefit in clin-
ical practice. Their application can enhance 
patient counselling by facilitating the sharing 
of information. Prognostic models can also 
support clinical decision-making through 
risk stratification and support treatment 
selection by predicting prognostic outcome 
across competing treatment strategies such 
as neoadjuvant and surgery-first management 
pathways.5
Despite a growing interest in prediction 
research and its methodologies6–12 there 
is a lack of rigorous application within 
surgical centres and wider surgical litera-
ture of predictive and prognostic models.5 
Conversely personalised precision medicine, 
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whereby predictive and prognostic modelling is used to 
forecast individual patient outcomes, is gaining prece-
dence within contemporary healthcare13 14 and creates an 
expectation for models to facilitate decision-making and, 
given the wider socioeconomic context, also guide cost-ef-
fective use of resources. Juxtapose these growing expec-
tations with the advent of neoadjuvant therapy making 
treatment options for resectable pancreatic cancer more 
complex, and it becomes clear that methods of predictive 
and prognostic modelling must be assessed if such chal-
lenges are to be overcome, as poor methods can result in 
unreliable and biassed results.12
The aim of this systematic review is to describe and 
assess the methodological quality of prediction research 
pertaining to model development studies that predict post 
resection prognosis of pancreatic ductal adenocarcinoma 
(PDAC). To our knowledge this is the first such system-
atic review of its kind. All methodological issues that are 
considered to be important in prediction research are 
critically analysed including reporting of: aim, design, 
study sample, definition and measurement of outcomes 
and candidate predictors, statistical power and analyses, 
model validation and results including predictive perfor-
mance measures.15
MethODS
The protocol for this review was published in the 
PROSPERO online database of systematic reviews 
(CRD42018105942). This review is reported according to 
the PreferredReporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) checklist.16
A search was undertaken using MEDLINE, Embase, 
PubMed, Cochrane database and Google Scholar. For 
each of the five searches, the entire database was included 
up to and including 31st July 2018 with no further date 
restrictions or limits applied. Full search strategies 
and date ranges are detailed in online supplementary 
appendix S1 (supporting information).
Patient and public involvement
Patients and the public were not involved in the design or 
conduct of this systematic review.
Study selection
After removal of duplicates, manual screening was carried 
out by first and second authors, based on the title and 
abstracts of articles identified in the database searches. 
Initial title screening was limited to English language. 
Where this identified relevant studies unavailable in 
English language translation was sought from colleagues 
fluent in the language in which the study was published. 
If this was not possible then language translation software 
was used.
Articles of probable or possible relevance to this review 
based on the title and abstract were reviewed in full. This 
was decided based on the inclusion criteria of prognostic 
modelling studies applied to the outcome of prognosis 
for patients with PDAC post resection. Prognostic model-
ling studies in this context included prognostic model 
development studies with and without external valida-
tion and external validation studies with model updating. 
We included only prognostic multivariable prediction 
studies where the aim was to identify a relationship 
between two or more independent variables and the 
outcome of interest to predict prognosis. We excluded 
predictor finding studies and studies that investigated 
a single predictor, test or marker. Studies investigating 
only causality between variables and an outcome were 
excluded. Model impact studies and external validation 
studies without model updating were excluded as the 
focus of this systematic review was on assessing the meth-
odological quality of prognostic model development.
Following screening, reference lists and citations of all 
included papers were manually searched to identify any 
additional articles. This process was repeated until no 
new articles were identified.
Data extraction, quality assessment and data analysis
Search design and data extraction was performed by the 
lead reviewer and with second author performing inde-
pendent data checking on all studies. Discrepancies were 
resolved by discussion between the reviewers. Data was 
extracted to investigate the methodological approach 
and reporting methods known to affect quality of multi-
variable predictive modelling studies and followed the 
Checklist for critical Appraisal and data extraction for 
systematic Reviews of prediction Modelling Studies 
(CHARMS) checklist.15 This checklist is designed for 
appraisal of all types of primary prediction modelling 
studies including emerging methods of neural network 
and vector machine learning.15
Data pertaining to the domains outlined in the 
CHARMS checklist were analysed and presented. These 
domains include: data sources, sample size, missing data, 
candidate predictors and model development, perfor-
mance and evaluation (table 1).15 Risk of bias assessment 
of included studies was performed according to the 
Prediction model Risk of Bias Assessment Tool.17
reSultS
Initial database searches revealed 23 097 studies that were 
screened manually by title and abstract. After first round 
of screening 263 studies underwent full text review with 
15 studies identified that satisfied the inclusion criteria 
(figure 1: PRISMA flowchart).
This review included a total of 15 model development 
studies, based on a total of 20 510 patients, published 
between 2004 and 2018. A full summary of included 
studies is provided in online supplementary appendix 
2 (supporting information) with risk of bias assess-
ment provided in online supplementary appendix 3 
(supporting information). The number of model devel-
opment studies, with (n=3)18–20 and without (n=12) 
external validation,21–32 increased sharply in recent years 
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Table 1 Summary of classification of domains from 
CHARMS checklist15
Domain Key information
Data source Registry data, randomised-controlled-trial 
data, case-control data, cohort data
Participant 
selection
Participant eligibility (inclusion/ exclusion 
criteria, description of participants, 
treatment received)
Recruitment methods (setting, location, 
number of centres, consecutive 
participants, study dates)
Model 
outcomes
Definition of outcomes: type (single or 
combined endpoints), was the same 
definition used in all participants?
Definition of methods for measuring 
outcomes: same in all participants, 
blinding, were candidate predictors part of 
the outcome?
Duration of follow-up or time of outcome 
occurrence reported
Candidate 
predictors
Number, type, definition, method and timing 
of measurement, was assessment blinded, 
how were candidate predictors handled 
within the model?
Sample size Number of participants and number of 
outcomes or events. Event per variable 
(number of outcomes / number of 
candidate predictors)
Missing data Number of participants with any missing 
data, number of participants with missing 
data for each predictor variable, methods 
for handling missing data
Model 
development
Modelling methods, methods for selecting 
predictors to include in multivariable 
analysis, methods and criteria for selection 
of predictors during multivariable analysis, 
shrinking of predictors or regression co-
efficients
Performance 
and evaluation
Calibration and discrimination with CIs, 
classification measures (sensitivity, 
specificity, predictive value etc), methods 
for testing performance, comparison 
of data distribution of predictors for 
development and validation data sets, 
in poor validation was model updating 
performed, alternative presentations of the 
model (nomogram, calculator, score etc)
Presentation 
of results and 
discussion
Comparison with other studies, 
generalisability, strengths and limitations
CHARMS, Checklist for critical Appraisal and data extraction for 
systematic Reviews of prediction Modelling Studies.
Figure 1 PRISMA 2009 flow diagram. Moher et al.16 PDAC, 
pancreaticductal adenocarcinoma; PRISMA, Preferred 
Reporting Items for Systematic Reviewsand Meta-Analyses.
Figure 2 Number of studies published (y-axis) in each year 
(x-axis).
(figure 2). Multivariable Cox regression proportional 
hazard regression was the most commonly employed 
modelling method (n=13)18–25 27–29 31 32 with two studies 
employing alternative machine learning techniques 
(Bayesian model: n=1; Artificial Neural Network (ANN): 
n=1).26 30 Six models could be applied preopera-
tively.19 23 24 27 28 31 Five studies focused on predicting poor 
prognosis (survival time under 7 months n=1, under 9 
months n=1, under 12 months n=2, 6, 12 and 18 months 
survival n=1).18 19 23 26 27 One model predicted prognosis of 
3 years or more.32 Seven models predicted prognosis at set 
time intervals (6 months, 1, 3 and 5 years n=1; 1, 2, 3 years 
n=2; 1, 3 years n=1 and 1, 3 and 5 years n=3).20–22 24 25 30 31 
Two studies did not categories survival time.28 29
Source of data, participant selection and follow-up
A cohort design, commonly recommended for prognostic 
model development,11 was used across all 15 models. Five 
studies used data from prospectively maintained data-
bases,19 20 22 27 29 with one of these studies collecting data 
prospectively alongside clinical trials.29 Seven studies 
used retrospective data.18 23–26 28 31 Three studies used data 
from the cancer data registry.21 30 32 Prospective cohort 
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Figure 3 Categories of candidate variables across all 
studies.
designed is recommended as it enables optimal measure-
ment of predictors and outcome.12 Retrospective cohorts 
are thought to yield poorer quality data11 but do enable 
longer follow-up time.12
Participant recruitment was well described with inclu-
sion criteria and description of cohort characteristics as 
well as study dates reported in all 15 studies. Length of 
follow-up time was clear in 14 studies.18–20 22–32 Consec-
utive sampling was reported in three studies18 24 26 but 
whether all consecutive participants were included, or 
number of participants who refused to participate, could 
not be evaluated as this was rarely reported across all 
studies. Non-consecutive sampling can introduce a risk of 
bias.33–35 The majority of models were developed using 
single centre databases (n=10)19 20 22–28 31 which can limit 
the generalisability of the model. This was followed by use 
of cancer registry database (n=3)21 30 32 and multicentre 
databases (n=2).18 29
Model outcomes
In all 15 studies outcomes were clearly defined with 
the same outcome definition and method of measure-
ment applied at all patients. However none of the 
studies reported blinding the outcome measurement 
for predictor values. Best practice dictates that assessor 
of the outcome occurrence should be blinded to ascer-
tainment of the predictor11 36 so as not to bias estima-
tion of predictor effects for the outcome.11 12 Although 
such a bias would not be a major factor in prediction of 
all cause mortality,12 15 the majority of studies predicted 
disease-specific prognosis, whereby bias could come into 
play in variables requiring subjective interpretation, such 
as results from imaging.15
Candidate predictors
A variety of candidate predictors were considered across 
all 15 model development studies (figure 3; table 2). The 
mean number of candidate predictors was 19.47 (range 
7 to 50). The definition, method and timing of measure-
ment of candidate predictors were clear across all 15 
studies although, as previously discussed lack of blinding 
was an issue. Three studies reported categorisation of 
candidate predictor variables prior to model develop-
ment.18 20 22 Ten studies specifically detailed how cate-
gorical data was analysed as non-binary.18 19 22–25 27 28 30 31 
Thirteen studies detailed how time-to-event data was anal-
ysed as non-binary.18–21 23–25 27–32 Handling such data as 
binary is not recommended practice as this can result in 
less accurate predictions, as with dichotomising predictor 
variables.37
Statistical power: sample size and missing data
Mean sample size was 1367 (range 50 to 6400). Event 
per variable (EPV) is the number of predictors assessed 
compared with the number of events. Statistical power of 
10 studies18 19 21 22 24 26 27 29 31 32 could be assessed using 
the recommended EPV rule of statistical power for Cox 
regression models of 10 events per candidate predictor, 
as determined by the smallest group.38–42 Of these studies 
five did not achieve statistical power according to this 
rule.18 19 24 26 31 Recently an EPV of 10 has been criticised 
as being too simplistic for calculating minimum sample 
size required for models predicting binary and time-to-
event outcomes.43 Instead there is a move toward applying 
the following three criteria to determine the minimum 
sample size required for such models: (i) predictor effect 
estimates defined by a global shrinkage factor of ≥0.9, (ii) 
small absolute difference in the model's apparent and 
adjusted Nagelkerke's R2 (≤0.05) and (iii) precise estima-
tion of the overall risk in the population.43 Initial testing 
of this approach suggests that it will minimise overfitting 
and ensure precise estimates of overall risk.43
Most studies (n=9) used complete case anal-
ysis.19–21 23 24 26–32 This approach results in loss of statis-
tical power and can introduce bias as missing data rarely 
occurs randomly and often pertains to participant or 
disease characteristics.12 Two studies reported missing 
data per candidate variable.22 28 One of these studies 
handled missing data by predicting input using regression 
modelling.22 The other study handled missing data by 
applying the Multivariate Imputation by Chained Equa-
tions method assuming data were missing at random.28 
Imputation, particularly multiple imputation, of missing 
data is advocated to reduce bias and maintain statistical 
power.44–46 Four studies did not give details of missing 
data.18 19 25 29
Model development
All 15 studies detailed how many candidate predictors were 
considered but none of the studies detailed how candidate 
predictors were selected with prior expert knowledge of 
disease inferred. One study selected predictors on multi-
variable analysis.22 Most studies (n=12) employed prese-
lection by univariable analysis of predictors for inclusion 
in multivariable analysis.18–21 23–25 27–29 31 32 Although this 
method is commonly employed it is not recommended as 
it carries a greater risk of predictor selection bias, particu-
larly in smaller sample sizes.47 Predictors not significant in 
univariable analysis may become significantly associated 
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Table 2 Summary of frequency of included variables in prognostic model development studies
Variable
Number of 
models variable 
is included in
Combined study 
population of all 
models in which 
the variable is 
included
Tumour grade 9 18 815
Age 8 17 565
Tumour stage 7 14 630
Tumour size 5 8154
Gender 4 12 910
Carbohydrate 
antigen (CA) 19-9
4 1815
Vascular 
involvement
3 1059
Tumour location 3 6858
T stage 3 10 433
Margin status 2 774
Lymph node 
involvement
2 794
Back pain 2 851
Carcinoembryonic 
antigen (CEA)
2 374
Lymph node ratio 2 6967
Co-morbidities 2 1036
Race 2 12 136
Splenectomy 1 555
Posterior margin 
positive
1 555
Weight loss 1 555
Platelet count 1 50
Neural Involvement 1 265
Neutrophil to 
lymphocyte ratio
1 265
Platelet to 
lymphocyte ratio
1 265
Albumin to globulin 
ratio
1 265
Quality of life 1 219
Adjuvant therapy 1 219
Radiotherapy 1 12 136
Alkaline phosphate 1 218
Albumin 1 218
Alkaline phosphate 
to albumin ratio
1 220
Geriatric nutritional 
index
1 296
Non-metastatic liver 
disease or insulin 
resistance
1 296
Marital status 1 6400
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with outcome following adjustment for other predictors.15 
Predictors preselected due to large but spurious associa-
tion with outcome can result in increased risk of over-
fitting.15 Furthermore multivariable analysis for predictor 
selection can result in overfitting and unstable models.12 
This is a particular risk when outcomes are few but many 
predictors are analysed.12 None of the studies described 
shrinkage technique as a method for addressing possible 
overfitting.15 In the case of low EPV, shrinkage methods 
could not account for all bias.15
Fourteen studies used backward elimination 
methods.18–21 23–32 This included an ANN that used single 
hidden layer back propagation to train the model,26 and a 
Bayesian model that employed backward step down selec-
tion process.30 Of the remaining 12 studies employing 
this method nominal p value was used as the criteria for 
predictor inclusion. Ten of these studies used p value 
<0.05,18 20 21 24 25 27–29 31 32 two of which also reported addi-
tionally using Akaike information criteria.28 29 One study 
used p value <0.1,23 and one study used p value <0.2 for 
univariate analysis and p value <0.1 for multivariate anal-
ysis.19 The use of a small p value has the benefit gener-
ating a model from fewer predictors but carries the risk 
of missing potentially important variables while the use of 
larger p values potentiates inclusion of predictors of less 
importance.15 One study reported using multivariable 
analysis for predictor selection determined by p value but 
then included non-significant factors in the final model 
to include all seven candidate variables, therefore effec-
tively employing full model approach.22 While full model 
approach can avoid selection bias,15 the potential for 
selection bias still remained in this study, as details were 
not given on how candidate predictors were decided.
Predictor selection can also incur bias when continuous 
predictors are categorised.15 Twelve studies reported 
categorisation.18–25 27 28 30 31 Three studies specifically 
stated that categorisation was performed prior to model-
ling.18 20 22 All 12 studies described appropriate statistical 
techniques for handling continuous variables.
Model performance and evaluation
Eight studies reported calibration of their 
model,18 19 21 22 25 30–32 most commonly presented as calibra-
tion curve. One study reported Hosmer-Lemeshow test,19 
a test sometimes criticised for limited statistical power to 
assess poor calibration and failure to indicate magnitude 
or direction of miscalibration.15 Twelve studies reported 
discrimination measured as either c-statistic (n=4)18 22 28 30 
or area-under-the-curve (AUC) of the receiver operated 
curve (n=4)19 20 23 26 or both (n=4).21 25 29 31 Although 
commonly used, the c-statistic can be influenced by 
predictor value distribution and be insensitive to inclu-
sion of additional predictors.15 Nine studies reported 
CIs with discrimination measures.18–22 25 28 30 31 R2 was 
reported in one study.19 Sensitivity and specificity were 
also poorly reported (n=2).26 29 Internal validation was 
rarely performed. Three studies used bootstrapping21 22 28 
and four studies used random split method.26 29–31 Three 
studies included external validation as part of model devel-
opment.18–20 However, the external validation data sets 
were small. Shen et al used 17 variables and the external 
validation data set contained only 61 patients.18 Balzano 
et al used 56 variables, using univariable analysis to select 
for multivariable analysis, but the derivation set had only 
78 patients and the external validation data set had only 
43 patients.19 In one of these studies it was unclear how 
many events occurred in the external validation cohort.20 
None of the studies described external validation of their 
models separate to the derivation authors and none of 
the studies described impact analysis of their models.
Presentation of results and discussion
Twelve studies presented both unadjusted and adjusted 
results of the full model with all candidate predictors 
considered18–21 23–25 27–29 31 32 and one study presented 
adjusted results only.22 All 15 studies offered alternative 
presentation of the model. The most common form 
of presentation of prognostic models was nomograms 
(n=5)18 21 22 25 31 and prognostic scores (n=5)19 24 27–29 
followed by prognostic calculators (n=3)26 30 32 and prog-
nostic index (n=2).20 23 All 15 studies reported interpreta-
tion of models as being for application to clinical practice 
and all studies discussed comparison, generalisability, 
strengths and weaknesses of their model as recommended 
by several guidelines including PRISMA statement.16
DISCuSSIOn
This systematic review has presented the current state 
of prognostic model development relating to prognosis 
following resection of PDAC. By assessing each domain 
of the CHARMS checklist across the 15 included studies, 
areas for improvement and direction for future research 
have been highlighted relating to general aspects of model 
development and reporting, applicability of models and 
sources of bias.15
General reporting
General reporting of aspects of model development 
was found to be clear relating to participant eligibility, 
recruitment and description as was reporting of follow-up 
period. Definitions of outcome and number and type of 
candidate predictors were also generally clearly reported 
across included studies. The most commonly included 
variables were tumour grade (n=9), age (n=8), tumour 
stage (n=7), tumour size (n=5), gender (n=4) and Ca 
19–9 (n=4). Vascular involvement, tumour location and 
tumour stage were each included in three predictive 
models. Although the number of participants was clearly 
reported, the number of events at defined times periods 
of prediction should be more clearly reported to assist 
assessment of statistical power. Improvement should also 
be made in the reporting of missing data. The majority 
of studies used complete case analysis but only two of the 
remaining studies provided details of missing data per 
variable.22 28 Across all 15 studies modelling methods were 
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clearly reported. Alternative presentations of models 
were also offered in all studies to assist application to clin-
ical practice with discussion on strengths, limitations and 
comparisons also offered.
Applicability
Generalisability of prognostic models is an area for 
improvement as the majority of models were based in 
single centre databases. The applicability of these models 
to patients in neoadjuvant treatment pathways has also 
not been assessed.
Methods of reporting model performance showed high 
heterogeneity with only nine studies providing CIs with 
results,18–22 25 28 30 31 making comment on general appli-
cability difficult. Most models had limited discriminatory 
performance with AUC below 0.7 and those reporting an 
AUC nearing 0.9 being based on small sample sizes there-
fore raising the possibility of overfitting. The two studies 
employing machine learning methods of ANN26 and 
Bayesian modelling30 did not report an improved AUC 
(0.6626 and 0.65,30 respectively). Furthermore calibration, 
a crucial aspect of model development, was frequently 
missing or not performed adequately with the calibration 
curve based on the derivation data set.25 In cases of poor 
validation whether the model was adjusted or updated 
was also poorly reported. Only three studies performed 
external validation18–20 and none of the studies explored 
impact analysis of their models making comment on 
the clinical application of the models difficult. Moving 
forward this could be addressed through access to data 
sets from meta-analyses of individual participant data, or 
registry databases containing electronic health records.48 
Such big data sets would allow researchers to externally 
validate, and where needed improve through recalibra-
tion, model performance across different settings, popu-
lations and subgroups.48
Source of bias
Areas for improvement were also found in limiting 
sources of bias. As previously mentioned overuse of 
single centre databases is one area but also the reporting 
of consecutive sampling, number of participants who 
refused participation and whether all consecutive partic-
ipants were included should be more clearly reported. 
Although handling of candidate predictors, and predic-
tors in modelling, were generally clearly reported 
including statistical methods for handling categorisation 
and non-binary variables, their assessment generally did 
not involve blinding to outcome. Assessment of statistical 
power of sample size was also not well reported and only 
two studies used the recommended approach of impu-
tation methods to handle missing data with the majority 
of studies employing complete case analysis which could 
both potentiate bias and reduce statistical power.15 None 
of the included studies gave details on how candidate 
predictors were identified. In selecting predictors for 
inclusion in the models the majority of studies employed 
preselection through univariable analysis followed 
by multivariable analysis. While such an approach is 
commonplace it does potentiate overfitting of models, 
an issue poorly discussed across all studies. Only three 
studies included external evaluation18–21 and classifica-
tion measures (sensitivity, specificity, predictive value) 
were poorly reported, as was comparison of distribution 
of predictors including missing data.
Future direction of research
The emerging focus on precision medicine means that 
the future application of predictive modelling will focus 
on personalised predictive modelling based on patient’s 
genomic and physiological data.5 The reality however is 
that such models are not yet in existence and current 
predictive and prognostic models are limited in scope 
and value with most only being descriptive in proba-
bilities of adverse events or survival outcomes.5 While 
this may help to manage patient expectations, existing 
models fall short in differentiating patients who would, 
and more importantly would not, benefit from partic-
ular treatment options.5 Furthermore some studies have 
shown that predictive and prognostic models are no 
better than experience led judgment.49 50 This is reflected 
in the limited application of predictive and prognostic 
models within surgical centres and the lack of rigorous 
application of predictive modelling in surgical literature.5 
To integrate fully into clinical practice predictive and 
prognostic models need to provide predictions beyond 
length of survival or risk prediction to include fundamen-
tals such as quality of survival time, length of hospital stay, 
resource utilisation and predicted benefits of competing 
treatment options available.
The first exciting steps in this path are starting to 
emerge with the recently published paper by Yama-
moto et al demonstrating that a mathematical model can 
successfully reproduce clinical outcomes using a predic-
tive signature for lower propensity to metastatic disease 
based on the finding that these primary tumours contain 
a small fraction of KRAS and CDKN2A, TP53, or SMAD4 
genes.51 Although this model requires prospective valida-
tion it indicates a future direction of research whereby 
PDAC treatment can be personalised to the most effec-
tive therapeutic modality. The next phase of research 
will be in integrating breakthroughs in genetic profiling 
into personalised predictive modelling. In summary, the 
patient with a favourable genetic profile making meta-
static disease from their primary PDAC less likely, but 
with other pre-existing comorbidities, will still want to 
know how likely they are to survive an operation and their 
risk of complications as well as quality adjusted survival 
predictions for all treatment options available. This is 
the future personalised predictive medicine supporting 
cost-effective healthcare.
To conclude, at a time when an increasing focus and 
expectation is being placed on personalised predictive 
medicine, this review highlights fundamental aspects 
of the methodological quality of models that must be 
improved if future models are to have a clinical impact by 
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supporting decision-making. While many of the models 
included in this review provided alternative presentations 
to assist in their clinical application, issues of methodolog-
ical quality were found that inhibited their clinical impact. 
These issues included how missing data is handled, the 
assessment of statistical power, issues of bias associated 
with candidate predictor selection and a lack of blinding 
during their assessment. Such issues are augmented by 
an over reliance on single centre databases which also 
limits the generalisability of the models. The reporting of 
model performance is also a key area for improvement. 
The emerging focus on precision medicine means that 
the future application of predictive modelling lies in 
combining each patient’s genomic and clinical data in a 
meaningful way that will support clinical decision-making 
at individual patient level. This can only be achieved if 
future research focuses on improving the methodological 
quality of model development, regardless of whether they 
employ traditional or machine learning methods.52
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